A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell nevus syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
- 20 Apr 2016 Results of PK analysis of BOLT study and pooled analysis of other three studies including this published in the Journal of Clinical Pharmacology.
- 08 Mar 2016 Results of pooled analysis of this and other trial (see profile:198479) presented at the 74th Annual Meeting of the American Academy of Dermatology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History